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Abstract
Cucurbitacin B (CuB), a potent antineoplastic agent of cucurbitacin triterpenoids, induces rapid disruption of actin
cytoskeleton and aberrant cell cycle inhibiting carcinogenesis. However, the underlying molecular mechanism of such
anticancer effects remains incompletely understood. In this study, we showed that CuB treatment rapidly induced
vasodilator-stimulated phosphoprotein (VASP) phosphorylation (i.e. activation) at the Ser157 residue and generated VASP
clumps which were co-localized with amorphous actin aggregates prior to the formation of highly-ordered cofilin-actin rods
in melanoma cells. Knockdown of VASP or inhibition of VASP activation using PKA-specific inhibitor H89 suppressed CuB-
induced VASP activation, actin aggregation and cofilin-actin rod formation. The VASP activation was mediated by cAMP-
independent PKA activation as CuB decreased the levels of cAMP while MDL12330A, an inhibitor of adenylyl cyclase, had
weak effect on VASP activation. Knockdown of either Ga13 or RhoA not only suppressed VASP activation, but also
ameliorated CuB-induced actin aggregation and abrogated cofilin-actin rod formation. Collectively, our studies highlighted
that the CuB-induced actin aggregation and cofilin-actin rod formation was mediated via the Ga13/RhoA/PKA/VASP
pathway.
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Introduction
Cucurbitacins are triterpenoid compounds isolated from
Cucurbitaceae plants that have been used as folk medicines for
centuries. They possess a broad spectrum of pharmacological
properties including cancer chemoprevention and anticancer
activity [1–4]. Several anticancer mechanisms of cucurbitacins
have been identified, such as inhibition of Janus kinase/signal
transducer and activator of transcription-3 (JAK/STAT3) signal-
ing [5–8], interference with mitogen-activated protein kinases
(MAPKs) pathway [6,8,9], induction of apoptosis [6,7,10,11], and
disruption of the actin cytoskeleton [9–17]. However, the precise
action target(s) for cucurbitacins is currently unknown. Although
cucurbitacins, including cucurbitacin B (CuB), are known as insect
steroid hormone antagonists acting on the ecdysteroid receptor
[18], the possibility that cucurbitacins target the ecdysteroid
receptor in mammalian cells could be excluded due to the lack of
such receptors in those cells [4]. Recently, increasing evidence
indicates that the actin cytoskeleton may be the common upstream
target for cucurbitacins to exert their pharmacological properties,
leading to cell deformation, multinucleated cell formation, cell
cycle arrest and cell motility inhibition [10,12,13].
Although the effect of cucurbitacins on the actin cytoskeleton
has been observed two decades ago [19] and studies repeatedly
demonstrate a rapid disruption of actin cytoskeleton by cucurbi-
tacins, the precise mechanism is still incompletely understood.
Several recent reports have shed new light on their action
mechanism for such actions. For example, some researchers
suggest that cucurbitacin E directly interacts with actin and
consequently stabilize the polymerized actin, although such an
effect was weak [20]. Others suggest that cucurbitacin causes actin
aggregation by indirectly interfering with actin dynamics [13]. In
supporting this, another study indicated that cofilin, a critical
actin-depolymerizing factor, might be a target of cucurbitacins
because it could bind to a synthesized biotin-linked cucurbitacin E,
and could be activated (i.e. dephosphorylated) by cucurbitacin E
and I [21]. This observation has been corroborated by our recent
studies showing that both CuB and cucurbitacin IIb induced
cofilin activation in melanoma cells [17], Jurkat cells [14] and
prostate cancer cells [22]. Interestingly, cofilin-actin rods were
formed after exposure to cucurbitacin IIb for more than 4 h, while
cell deformation and actin aggregation were induced much earlier
[22]. Consistent with its action on the actin cytoskeleton, CuB
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substantially changed the expression of many actin-regulating
factors as revealed by quantitative proteomic analysis [12]. It is
worth noting that CuB treatment could upregulate the expression
of vasodilator-stimulated phosphoprotein (VASP) [12], suggesting
that it has a potential role in CuB-induced disruption of the actin
cytoskeleton.
VASP is an important member of Enabled/vasodilator-stimu-
lated phosphoprotein (Ena/VASP) family [23]. Several multi-
functional actin-modulating proteins belong to this family, which
localize at regions where actin is dynamically remodeled and new
filaments are formed [24,25]. VASP constitutively or stimulus-
dependently localizes at the filopodia or lamellipodia, acting as an
F-actin barbed end binding protein to facilitate actin filament
elongation by interacting with G-actin, profilin and other actin
regulatory factors [26,27]. VASP can also directly regulate the
assembly of the actin-filament network, modulates the morphology
and behavior of membrane protrusion structures, and functions in
cell migration and adhesion [23,24,28]. These observations
support that VASP plays a critical role in remodeling actin
cytoskeleton in cells. As VASP has an essential role in linking
signaling pathways to remodeling the actin cytoskeleton, we
hypothesized that VASP might participate in the process of actin
aggregation and reorganization induced by cucurbitacins. In this
study, we sought to explore the role of VASP in CuB-induced
disruption of actin cytoskeleton in human A375 and mouse
B16F10 melanoma cell lines. Our results provided evidence that
CuB induces actin aggregation and cofilin-actin rod formation
through activation of the Ga13/RhoA/PKA/VASP pathway.
Materials and Methods
Chemicals
Cucurbitacin B (molecular weight 558.7 Da) with 98% purity
was obtained from Zhongxin Innova Laboratories (Tianjin,
China), dissolved in dimethyl sulfoxide (DMSO) at 10 mM, and
stored at 220uC. N-acetyl-L-cysteine (NAC), H89, MDL12330A,
dithiothreitol (DTT), propidium iodide, and DMSO were from
Sigma-Aldrich (St Louis, MO, USA). RNase A was purchased
from Invitrogen (Carlsbad, CA, USA). Forskolin was obtained
from Calbiochem/Millipore (Billerica, MA, USA).
Cell culture
Human A375 and murine B16F10 melanoma cell lines were
obtained from the Cell Bank of the Chinese Academy of Sciences
(Shanghai, China). Cells were cultured in DMEM (Invitrogen)
supplemented with 10% fetal bovine serum (FBS) (Invitrogen),
100 U/ml penicillin, and 100 mg/ml streptomycin (Invitrogen),
and maintained at 37uC in a humidified incubator of 5% CO2.
Immunofluorescence microscopy
After incubation with CuB (0.1 mM), cells were fixed in 4%
paraformaldehyde prepared in phosphate-buffered saline (PBS),
permeabilized with ice-cold 100% methanol, and immunostained
with mouse anti-b-actin (1:500; Cell Signaling Technology) or
rabbit anti-VASP (1:300; Cell Signaling Technology), followed by
CF488-conjugated goat-anti-mouse IgG (1:700) or CF568-conju-
gated goat-anti-rabbit IgG (1:700), highly cross-absorbed (Biotium,
Hayward, CA, USA). Nuclei were revealed by Hoechst33342
(5 mg/ml) staining. Fluorescence images were observed and
collected under a Leica DMIRB fluorescent microscope (Leica
Microsystems, Wetzlar, Germany) armed with a Spinning Disk
Confocal Microscopy system (UltraView cooled CCD; Perkin
Elmer, Waltham, MA, USA).
Co-localization analysis
All fluorescence image analysis was conducted using ImageJ
software (National Institutes of Health, Bethesda, MD). Co-
localization analysis was performed using intensity correlation
analysis (ICA) method as described previously [29]. The PDM
value is the Product of the Differences from the Mean, i.e. for each
pixel: PDM = (red intensity – mean red intensity 6 (green
intensity – mean green intensity). PDM images were created using
a plugin for ImageJ found at http://www.uhnresearch.ca/
facilities/wcif/imagej/colour_analysis.htm#coloc_coeff. ICA pro-
duces a PDM image of graded co-localization, where positive
PDM value correspond to a high degree of co-localization (here
maximum values shown in yellow, negative values shown in blue).
The Intensity Correlation Quotient (ICQ) values are equal to the
ratio of the number of positive PDM values to the total number of
pixel values. From this ratio, 0.5 is subtracted to yield ICQ values
distributed between 20.5 and +0.5 where random co-localization
gives an ICQ of , 0, segregated or asynchronous co-localization
gives 20.5 , ICQ # 0, and synchronous co-localization yields 0
, ICQ # + 0.5.
cAMP assay
A375 cells (1 6 105 cells/ml, 100 ml) were seeded in 96-well
plates and incubated overnight at 37 uC. On the next day, culture
medium was replaced by serum free medium. As indicated in the
figure legends, A375 cells were treated with CuB (0.1 mM and
1 mM), Forskolin (10 mM, positive control) and pretreated with
H89 (20 mM) or MDL12330A (10 mM) for 1 h followed by CuB
treatment, respectively. cAMP was measured using a Cyclic AMP
XPTM Assay Kit (Cell Signaling Technology) according the
manufacturer’s directions.
Extraction of soluble actin
Soluble actin (referred as G-actin hereafter) was extracted as
described previously [12]. Briefly, cells were treated with CuB and
pretreated with SP600125 (20 mM) or NAC (10 mM) for 1 h
followed by CuB (0.1 mM) treatment, respectively. Then, the cells
were washed twice with cold PBS (4uC) and G-actin was extracted
with soluble actin extraction solution (containing 0.2% Triton X-
100) from the cells. The residues (F-actin) were lysed using
26loading buffer for sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE).
Cell proliferation assay
Cell proliferation was measured by MTS assay using the
CellTiter 96 Aqueous ONE Solution kit (Promega, Madison, WI).
Briefly, cells were seeded into 96-well plates at a density of 46104/
ml and 100 ml/well for 24 h. On the next day, culture medium
was replaced. A375 cells were treated with CuB (0.01 mM, 0.1 mM
and 1 mM) alone or pretreated with SP600125 (20 mM) for 1 h
followed by CuB treatment for 48 h then measured using MTS
assays. MTS reagent (20 ml) was added to each well and incubated
at 37uC for 1 h–4 h. The absorbance at 490 nm was measured
using a microplate reader (Model 680; Bio-Rad, Richmond, CA).
Three independent experiments were performed, each in tripli-
cates.
Western blot analysis
Samples were prepared as described above or by lysing PBS-
washed cells with RIPA buffer (Beyotime, Haimen, China). The
proteins were separated by SDS-PAGE followed by electro-
transfer to polyvinylidene difluoride membrane (Hybond-P; GE
Healthcare Life Sciences, Piscataway, NJ). The membrane was
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probed using antibodies against phospho-VASP (1:1000), VASP
(1:1000), phospho-cofilin (1:1000), cofilin (1:1000), b-tubulin
(1:2000) (Cell Signaling Technology), Ga13 (1:2000; Abgent),
RhoA (1:2000; Abgent) and pan-actin (1:2000; Santa Cruz
Biotechnology, Santa Cruz, CA), followed by a horseradish
peroxidase (HRP)-conjugated second antibody (1:10000) (Jackson
ImmunoResearch, West Grove, PA). Bands were revealed with
enhanced chemiluminescence kit (BeyoECL Plus; Beyotime) and
recorded on X-ray films (Kodak; Xiamen, Fujian, China). The
densitometry of each band was quantified by FluorChem 8000
(AlphaInnotech, San Leandro, CA).
RNA interference assay
Small interfering RNA (siRNA) duplexes targeting VASP (59-
GGACCUACAGAGGGUGAAAdTdT-39) were designed and
synthesized by RiboBio (Guangzhou, China). The siRNA duplexes
(#6267) targeting cofilin was obtained from Cell Signaling
Technology. The siRNA of Ga13 (#RI12255) and RhoA
(#RI14534) were obtained from Abgent (Suzhou, China).
Transfection was performed using N-TER Nanoparticle siRNA
Transfection System (Sigma-Aldrich) according to the manufac-
turer’s protocol. In brief, 16104 A375 cells were plated in 35-mm
dishes and cultured overnight. VASP (20 nM), Cofilin (40 nM),
Ga13 (40 nM), RhoA (40 nM) and negative control siRNA
(20 nM) were transfected into cells, respectively. After 72 h
incubation at 37uC, the silencing efficiency was determined by
Western blot using specific antibodies. After knockdown for 72 h,
the effect of CuB on VASP phosphorylation and actin cytoskeleton
were measured by western blot and immunofluorescence micros-
copy.
Statistical analysis
All experiments were performed in triplicate, with one
representative experiment shown. Data were expressed as mean
6 SD. Statistical analysis was performed using GraphPad Prism
4.0 (GraphPad Software Inc., San Diego, CA). One-way ANOVA,
followed by Dunnett’s multiple comparison tests (versus control),
was used to analyze the statistical significance among multiple
groups. P values , 0.05 were considered statistically significant.
Results
CuB-induced VASP phosphorylation and clustering
correlate with actin aggregation
Whereas CuB is well known for its actin cytoskeleton-disrupting
activity in various cancer cells [9,12,14–16], the underlying
mechanism is incompletely understood. In view of the critical
role of VASP in linking signaling pathways to the actin
cytoskeleton remodeling, we tested whether this protein is involved
in the process of CuB-induced actin aggregation. The function of
VASP has been shown to be regulated by phosphorylation at three
distinct residues (serine 157 (Ser157), serine 239 (Ser239), and
threonine 278 (Thr278) residues) [30]. In this study, we showed
that VASP was phosphorylated at Ser157 by CuB treatment in a
time- and dose-dependent manner in both A375 (Figure 1, A and
B) and B16F10 (Figure S1A in File S1) melanoma cells. The
phosphorylation of VASP at Ser157, but not Ser239 or Thr278,
led to an electrophoretic mobility shift from 46 to 50 kDa in SDS-
PAGE [23,30]. These results suggest that VASP may be involved
in CuB-induced actin aggregation.
Next we used immunofluorescence microscopy to explore the
localization of VASP in CuB-treated cells. Whereas VASP was
diffusely distributed and only slightly co-localized with the actin at
the leading edge as well as punctuate actin in control cells, it was
locally clustered and co-localized with actin aggregates (hereafter
referred to as VASP-actin clusters) upon CuB treatment for 0.5 h
(Figure 1, C and D; Figure S1B in File S1). Four hours later, most
of the VASP formed large aggregates which were still co-localized
with the amorphous actin aggregates, but unexpectedly, not with
the rod-like actin structures (Figure 1C). Concomitant with the
aggravation of CuB-induced actin aggregation (Figure 1C), the
levels of phosphorylated VASP were markedly increased over time
(Figure 1B). Notably, we found that those rod-like actin structures
were highly co-localized with cofilin rods (Figure 1E), in agreement
with previous observation that these rods were actually cofilin-
actin rods [17,22]. In cofilin siRNA-transfected cells, CuB-induced
VASP phosphorylation was even enhanced at 0.5 h, and then
returned back to similar level to control later (4 h) (Figure 1F).
Meanwhile, the cofilin-actin rod formation was substantially
suppressed when cofilin was knocked down (Figure 1G). Interest-
ingly, although the cofilin-actin rods did not co-localize with the
VASP-actin clusters, it seemed that most of them were protruded
from these clusters (Figure 1C, 4 h and Figure 1D). These results
suggest that the actin aggregation, as well as the remodeling of
amorphous actin clusters into cofilin-actin rods by CuB treatment,
is dynamically regulated by VASP activation.
VASP is required for the reorganization of CuB-induced
actin aggregates into cofilin-actin rods
As CuB treatment caused cell deformation and actin aggrega-
tion followed by remodeling actin aggregates into cofilin-actin
rods, we further explored the role of VASP in these processes by
siRNA knockdown of its expression in A375 cells. Western blotting
showed that VASP levels were reduced by nearly 80% at 72 h post
transfection (Figure 2A). Knockdown of VASP slightly enlarged
the cell size as observed by phase contrast microscopy (Figure 2B).
When cultured with CuB for 0.5 h, the cell deformation was
significantly suppressed in VASP-knockdown cells compared with
that in controls. Notably, 4-h CuB treatment generated dendritic-
like cells in VASP siRNA-transfected group in contrast to oval or
rounded cells in control siRNA-transfected sample (Figure 2B,
4 h). Consistent with these results, immunofluorescence micros-
copy revealed that knockdown of VASP, hence reducing its
activation, markedly diminished CuB-induced actin aggregation
upon 0.5-h exposure to CuB treatment and fully abolished actin
rod formation after 4-h CuB treatment, although actin aggregation
still took place (Figure 2C). Unexpectedly, cofilin activation was
unchanged upon VASP knockdown (Figure 2A), indicating that
the activation of cofilin is insufficient, though indispensable, to
induce cofilin-actin rods by CuB treatment. These results also
Figure 1. Cucurbitacin B (CuB) induced VASP phosphorylation and clustering in A375 cells. (A,B) Western blot analysis showing the dose-
(A) and time- (B) dependent effect of CuB on VASP phosphorylation. (C) Immunofluorescence microscopy analysis showing the co-localization
(yellow) of VASP (red) and actin (green) with nuclei (blue) counter staining after 0.1 mM CuB treatment. (D) Co-localization analysis of VASP and actin
of C. Both PDM images and ICQ values (right panel) are shown. (E) CuB induced cofilin-actin rod formation. Cells were immunostained with anti-b-
actin (green) and anti-cofilin (red) antibodies with nuclei (blue) counter staining. (F) Influence of cofilin knockdown on CuB-induced VASP activation.
(G) Influence of cofilin knockdown on actin distribution. Magnified images of the boxed areas (merged images) are presented in C, E and G. Scale
bars: 10 mm (5 mm in magnified images).
doi:10.1371/journal.pone.0093547.g001
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Figure 2. VASP knockdown mitigated CuB (0.1 mM)-induced actin aggregation, cofilin-actin rod formation and cell deformation. (A)
Knockdown of VASP did not affect CuB-induced cofilin dephosphorylation as revealed by western blot analysis. (B) Effect of VASP knockdown on CuB-
induced cell deformation as observed using phase-contrast microscopy. Scale bars: 20 mm. (C) Immunofluorescence microscopy analysis of the
influence of VASP (red) knockdown on CuB-induced actin (green) aggregation. Scale bars: 10 mm (5 mm in magnified images).
doi:10.1371/journal.pone.0093547.g002
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suggested that VASP had participated in the formation of actin
aggregates upon CuB treatment and was necessary for reorganiz-
ing those amorphous actin clusters into highly-ordered cofilin-
actin rods.
CuB-induced VASP phosphorylation is mediated by
cAMP-independent PKA activation
It has been reported that Ser157 residue of VASP is
preferentially phosphorylated by the cAMP-dependent protein
kinase A (PKA) [31]. To determine whether cAMP/PKA
signaling is involved in CuB-induced VASP phosphorylation,
A375 cells were pretreated with H89, a selective inhibitor of PKA,
or MDL12330A, an adenylyl cyclase inhibitor that blocks cAMP
production, prior to CuB treatment. The phosphorylation of
VASP (Ser157) was subsequently analyzed. The results showed
that CuB-induced VASP phosphorylation was profoundly sup-
pressed by H89 pretreatment (Figure 3A). MDL12330A pretreat-
ment also suppressed CuB-induced VASP phosphorylation, but
Figure 3. H89, but not MDL12330A (MDL), pretreatment suppressed CuB-induced VASP activation, actin aggregation and cell
deformation. (A) Western blotting showing the effects of H89 and MDL pretreatment on CuB-induced VASP activation and cofilin
dephosphorylation. (B,C) CuB decreased the levels of cAMP in a time- and dose-dependent manner (B). H89 and MDL pretreatment affected the
levels of cAMP in CuB-treated cells (C). The cAMP level of forskolin (10 mM)-treated cells was set as 100% activity (B,C). (D) Immunofluorescence
analysis of the influence of H89 pretreatment on the distribution of VASP (red) and actin (green) in CuB-treated cells. Scale bars: 10 mm (5 mm in
magnified images). (E) Co-localization analysis of VASP and actin of D. (F) Effect of H89 pretreatment and MDL pretreatment on CuB-induced cell
deformation as observed using phase-contrast microscopy. Magnified images of the boxed areas are presented on the right. Scale bars: 20 mm.
doi:10.1371/journal.pone.0093547.g003
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was less effective compared to H89. In B16F10 cells, H89 also
inhibited CuB-induced VASP phosphorylation, whereas
MDL12330A did not (Figure S1C in File S1). These observations
prompted us to consider whether CuB induces the production of
cAMP. Surprisingly, cAMP level was decreased by CuB treatment
in a time- and dose-depended manner (Figure 3B). As expected,
both H89 and MDL12330A pretreatment caused a decrease of
cAMP in control cells; MDL12330A pretreatment further
decreased the production of CuB-induced cAMP (Figure 3C),
but VASP phosphorylation remained at a high level (Figure 3A,
0.5 h). These results indicate that the kinase activity of PKA, being
independent of cAMP and adenylyl cyclase activity, is required for
CuB-induced VASP phosphorylation at Ser157 residue.
To further investigate the functional consequence of PKA
inhibition, we analyzed the effect of H89 on CuB-induced
aggregation of VASP and actin using immunofluorescence
microscopy. Blocking the kinase activity of PKA with H89 and
thereby suppressing the activation of VASP (Figure 3A) effectively
inhibited actin and VASP aggregation upon 0.5-h CuB exposure
(Figure 3D, Figure S1D in File S1). The formation of CuB-induced
cofilin-actin rod was also suppressed by H89 pretreatment
(Figure 3D). Although at 4-h CuB incubation it was slightly
higher than control, the ICQ value at 0.5-h CuB incubation in the
presence of H89 was comparable to the control treated with H89
alone (Figure 3E), indicating that H89 reduced CuB-induced co-
localization between VASP and actin. Furthermore, similar to the
action of VASP-knockdown, H89 pretreatment suppressed CuB-
induced cell deformation at 0.5 h, and resulted in more dendritic-
like cells at 4 h of CuB exposure. By contrast, MDL12330A
pretreatment did not affect CuB-induced cell deformation
(Figure 3F). Together, although H89 was unable to fully block
actin aggregation, these results demonstrate that CuB-induced
actin aggregation is mainly mediated by cAMP-independent
PKA/VASP activation.
Ga13 and RhoA are upstream components of CuB-
induced PKA/VASP signaling
Next, we explored whether Ga13/RhoA signaling, which has
been reported to function in modulating VASP activity [32], is
involved in regulating CuB-induced and PKA-mediated phos-
phorylation of VASP at Ser157 residue. Initially, western blot
analysis showed that the protein levels of Ga13 and RhoA were
not affected by CuB treatment (Figure 4A). However, when Ga13
and RhoA genes in A375 cells were knocked down by siRNA,
CuB-induced VASP activation was diminished as compared with
control siRNA-treated cells (Figure 4, B and C). Moreover,
knockdown of RhoA, but not Ga13, temporarily rescued cofilin
dephosphorylation after exposure to CuB for 0.5 h (Figure 4B),
suggesting that RhoA signaling participated in CuB-induced
cofilin activation. Interestingly, knockdown of either RhoA or
Ga13 markedly enlarged the cell size (Figure 4, D-F), and
profoundly suppressed the actin aggregation (Figure 4D) and cell
deformation (Figure 4F) induced by CuB treatment for 0.5 h. The
cofilin-actin rods which should be induced by 4-h CuB treatment
were also abrogated by either RhoA or Ga13 knockdown
(Figure 4, D and E). Similar to the effect of VASP-knockdown,
RhoA- or Ga13-knockdown resulted in scattered distribution of
actin aggregates (Figure 4D) and dendritic-like cells (Figure 4F)
upon CuB treatment for 4 h. Together, these results indicate that
CuB-induced VASP activation is mediated by the Ga13/RhoA/
PKA signaling pathway.
Discussion
Emerging evidence indicates that cucurbitacin B (CuB), like
other cucurbitacins, induces a rapid damage to the actin
cytoskeleton in tumor cells. Although it has been intensively
explored by researchers for many years, the underlying mecha-
nism is still not well understood [9,12,15,19]. We reported here
that Ga13/RhoA/PKA signaling-mediated VASP phosphoryla-
tion plays a critical role in CuB-induced actin aggregation and
cofilin-actin rod formation. Such actin-damaging effects of CuB, as
well as PKA-mediated phosphorylation at Ser157 residue of VASP
in response to CuB treatment, are either significantly suppressed
or fully blocked upon knockdown of Ga13 or RhoA gene
expression. These findings are in agreement with the previous
report that Ga13-regulated RhoA and PKA activity controls
cytoskeletal rearrangement via a cAMP-independent mechanism
[32].
The mammalian Ena/VASP proteins, including VASP, have
important roles in linking signaling pathways to remodeling of the
actin cytoskeleton [24,33]. VASP translocation to the cell
periphery depends on Ser157 phosphorylation, while regulation
of F-actin assembly by VASP does not require the phosphorylation
of its Ser157 residue [30]. High local concentrations of VASP, or
high ratio of VASP to actin, may intensify the regulatory activity of
VASP in actin reorganization [34]. Concomitant with CuB-
induced VASP phosphorylation at Ser157, we observed that
VASP was firstly accumulated and aggregated in the cell periphery
where actin aggregates initiated upon CuB treatment. Subse-
quently, the aggregated VASP was closely co-localized with actin
Figure 4. Ga13 and RhoA were involved in CuB-induced VASP activation and actin cytoskeleton disruption. (A) The expression of Ga13
and RhoA was not affected after CuB treatment as evidenced by western blotting. (B,C) Western blot analysis showing the effect of RhoA (B) or Ga13
(C) knockdown on CuB-induced VASP activation and cofilin dephosphorylation (B,C) and JNK activation (C). (D,E)Immunofluorescence microscopy
analysis showing the distribution of RhoA (green) and actin (red) in of RhoA-knockdown cells (D) and the distribution of VASP (red) and actin (green)
in Ga13-knockdown cells (E). Scale bars: 10 mm (5 mm in magnified images). The white arrowheads indicate the cell in which Ga13 was knocked down
(E). (F) Effect of Ga13 and RhoA knockdown on CuB-induced cell deformation observed using phase-contrast microscopy. Scale bars: 20 mm.
doi:10.1371/journal.pone.0093547.g004
Figure 5. A proposed mechanism depicts CuB-induced actin
aggregation and VASP activation via the Ga13/RhoA/PKA
pathway. Dashed arrows and question marks indicate unidentifed/
unconfirmed signaling components.
doi:10.1371/journal.pone.0093547.g005
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aggregates. Afterwards, cofilin-actin rods protruded from the
VASP-actin clusters. Such distinct redistribution patterns of VASP
upon CuB treatment suggest that VASP may be involved in
remodeling the actin aggregates into highly-ordered cofilin-actin
rods. This notion is supported by the observations that VASP
activation was positively correlated with the severity of actin
cytoskeleton disruption and G-actin pool depletion and that VASP
knockdown markedly suppressed CuB-induced actin aggregation
and completely blocked the cofilin-actin rod formation. Consistent
with previous studies indicating that VASP promotes G-actin
incorporation at growing filament ends [24] while phosphorylation
of VASP at Ser157 reduces its ability to bind to G-actin [25,33],
our results indicate that VASP plays a crucial role in CuB-induced
actin cytoskeleton reorganization.
Considering the importance of VASP activation in disruption of
the actin cytoskeleton organization by CuB treatment, we have
also attempted to identify the upstream components controlling
the phosphorylation of VASP. Consistent with previous observa-
tions [31], CuB-induced VASP phosphorylation at Ser157 was
mediated by PKA since it could be inhibited by the selective PKA
inhibitor H89. PKA is well known to be activated by cAMP, which
is generated by adenylyl cyclase [35]. However, CuB treatment
did not increased but instead decreased the levels of cAMP in cells.
Furthermore, CuB-induced VASP activation was not very
sensitive to adenylyl cyclase inhibitor MDL12330A, which
markedly decreased cAMP production. Therefore, CuB-induced
phosphorylation of VASP at Ser157 was mediated by cAMP-
independent PKA activation.
It has been reported that, in addition to being activated by
cAMP, PKA can also be activated by the Ga13/RhoA pathway,
leading to the phosphorylation of VASP [32]. Ga13 is a member
of the large family of G-proteins that are linked with G-protein
coupled receptors (GPCRs) to transmit extracellular stimuli to
intracellular signaling cascades [36,37]. Among the G-proteins,
Ga13 mediates the signaling of Rho (RAS homology) family
members that regulate reorganization of the actin cytoskeleton
[36–38]. Interestingly, we found that CuB-induced VASP
phosphorylation at Ser157, actin aggregation and cell deformation
were all inhibited either by RhoA knockdown or by Ga13
knockdown. These results established that CuB-induced VASP
activation was mediated by PKA activation via the Ga13/RhoA
signaling pathway. Further supporting our observation, actin
cytoskeleton disruption induced by cucurbitacin IIa and cucurbi-
tacin I is associated with increased activity of RhoA [11,39].
Moreover, due to the critical role of Rho proteins in regulating
actin cytoskeleton, bacterial toxins targeting these proteins lead to
actin aggregation similar to the action of CuB [40]. However, it is
still unclear how cAMP-independent PKA was activated by CuB-
induced Ga13/RhoA signaling. It has been reported that Ga13-
induced VASP phosphorylation may lead to activation of RhoA
and MEKK1, phosphorylation and degradation of IkB, release of
PKA catalytic subunit from the complex with IkB and NF-kB, and
subsequent phosphorylation of VASP [32]. Whether similar
mechanism is involved in CuB-induced PKA activation needs
further investigation. Collectively, we provided evidence that the
Ga13/RhoA/PKA axis plays a critical role in mediating CuB-
induced VASP activation, resulting in actin aggregation and
cofilin-actin rod formation (Figure 5).
In summary, we demonstrated that VASP activation mediated
by the Ga13/RhoA/PKA pathway plays a crucial role in CuB-
induced actin aggregation and cofilin-actin rod formation.
However, it is still unknown how Ga13 is activated by CuB.
Notably, the chemical structure of the skeleton of cucurbitacin
type tetracyclic triterpenoids is similar to that of other sterols
[37,41], such as cholesterol (Figure S2 in File S1). Cucurbitacins,
including CuB, can compete for ecdysteroid receptors in insects
[18]. Although ecdysteroid receptors are not present in mamma-
lian cells, a number of mammalian GPCRs are reportedly
modulated by cholesterol, the most abundant component of
eukaryotic membranes [42,43]. Thus, it is probable that CuB as
well as other cucurbitacins may act on certain GPCRs linked with
Ga13 (Figure 5). Further works are warranted to clarify the exact
GPCR(s) targeted by cucurbitacins.
Supporting Information
Figure S1 CuB-induced VASP phosphorylation (activa-
tion) was mediated by PKA in CuB-treated B16F10 cells.
(A) Western blotting showing that VASP was rapidly phosphor-
ylated in a dose- and time-dependent manner in CuB-treated cells.
(B, D) Immunofluorescence microscopy analysis of VASP (red)
and actin (green) in CuB (1 mM) -treated cells in the absence (B) or
presence of PKA inhibitor H89 (D). Colocalization analysis of
VASP and actin was performed and both PDM images and ICQ
values (lower panel) are shown. Scale bars: 10 mm (5 mm in
magnified images). (C) Effect of H89 or MDL12330A (MDL)
pretreatment on CuB-induced VASP activation. CuB, 0.5 h.
(DOC)
Figure S2 Chemical structure of CuB and cholesterol.
(A) The basic skeleton of cucurbitane. (B) Chemical structure of
CuB. (C) Chemical structure of cholesterol.
(DOC)
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